{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:46:46Z","timestamp":1787503606566,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>\n                    Solid organ transplant (SOT) recipients have a higher risk of developing invasive mould diseases (IMD). Isavuconazole is a novel broad-spectrum azole active against\n                    <jats:italic>Aspergillus<\/jats:italic>\n                    spp. and Mucor, well tolerated, with an excellent bioavailability and predictable pharmacokinetics, that penetrates in most tissues rapidly, and has few serious adverse effects, including hepatic toxicity. Contrary to other broad-spectrum azoles, such as voriconazole and posaconazole, isavuconazole appears to show significant smaller drug-drug interactions with anticalcineurin drugs. We have performed an extensive literature review of the experience with the use of isavuconazole in SOT, which included the SOTIS and the ISASOT studies, and published case reports. More than 140 SOT recipients treated with isavuconazole for IMD were included. Most patients were lung and kidney recipients treated for an\n                    <jats:italic>Aspergillus<\/jats:italic>\n                    infection. Isavuconazole was well tolerated (less than 10% of patients required treatment discontinuation). The clinical responses appeared comparable to that found in other high-risk patient populations. Drug-drug interactions with immunosuppressive agents were manageable after the reduction of tacrolimus and the adjustment of mTOR inhibitors at the beginning of treatment. In conclusion, isavuconazole appears to be a reasonable option for the treatment of IMD in SOT. More clinical studies are warranted.\n                  <\/jats:p>","DOI":"10.3389\/ti.2023.11845","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T23:11:39Z","timestamp":1702595499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients"],"prefix":"10.3389","volume":"36","author":[{"given":"Jose Tiago","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s15010-019-01360-z","article-title":"Invasive Mould Infections in Solid Organ Transplant Patients: Modifiers and Indicators of Disease and Treatment Response","volume":"47","author":"Welte","year":"2019","journal-title":"Infection"},{"key":"B2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.idc.2018.04.006","article-title":"Mold Infections in Solid Organ Transplant Recipients","volume":"32","author":"Lemonovich","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ccm.2017.04.011","article-title":"Fungal Infections After Lung Transplantation","volume":"38","author":"Kennedy","year":"2017","journal-title":"Clin Chest Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e14049","DOI":"10.1111\/tid.14049","article-title":"Invasive Aspergillosis in Liver Transplant Recipients","volume":"25","author":"Melenotte","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/ajt.16248","article-title":"Risk Factors for the Development of Invasive Aspergillosis After Kidney Transplantation: Systematic Review and Meta-Analysis","volume":"21","author":"Perez-Jacoiste Asin","year":"2021","journal-title":"Am J Transpl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12879-021-05958-3","article-title":"Invasive Aspergillosis in Solid Organ Transplant Patients: Diagnosis, Prophylaxis, Treatment, and Assessment of Response","volume":"21","author":"Neofytos","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive Summary of Clinical Practice Guideline for the Management of Invasive Diseases Caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Garcia-Vidal","year":"2019","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and Management of Aspergillus Diseases: Executive Summary of the 2017 ESCMID-ECMM-ERS Guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0213-005X(12)70082-4","article-title":"Fungal Infection in Solid Organ Recipients","volume":"30","author":"Fortun","year":"2012","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global Guideline for the Diagnosis and Management of Mucormycosis: An Initiative of the European Confederation of Medical Mycology in Cooperation With the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/myc.12283","article-title":"Comparison of Nephrotoxicity Associated to Different Lipid Formulations of Amphotericin B: A Real-Life Study","volume":"58","author":"Falci","year":"2015","journal-title":"Mycoses"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12751","article-title":"Drug-Drug Interactions Between Triazole Antifungal Agents Used to Treat Invasive Aspergillosis and Immunosuppressants Metabolized by Cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New Perspectives on Antimicrobial Agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e00305-17","DOI":"10.1128\/AAC.00305-17","article-title":"Combination Therapy With Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis","volume":"61","author":"Petraitis","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0178421","DOI":"10.1128\/spectrum.01784-21","article-title":"Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)","volume":"10","author":"Monforte","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/TP.0000000000004312","article-title":"Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-Life Clinical Practice","volume":"107","author":"Fernandez-Ruiz","year":"2023","journal-title":"Transplantation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13501","DOI":"10.1111\/tid.13501","article-title":"Invasive Pulmonary Aspergillosis Associated With COVID-19 in a Kidney Transplant Recipient","volume":"23","author":"Trujillo","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9839780","DOI":"10.1155\/2019\/9839780","article-title":"Gastric Mucormycosis in a Renal Transplant Patient Treated With Isavuconazole Monotherapy","volume":"2019","author":"Gani","year":"2019","journal-title":"Case Rep Transpl"},{"key":"B19","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.mycmed.2021.101235","article-title":"Intricate Isavuconazole Therapy of a Subcutaneous Nodule Caused by Alternaria Infectoria in a Heart Transplant Recipient","volume":"32","author":"Maisons","year":"2022","journal-title":"J Mycol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13197","DOI":"10.1111\/tid.13197","article-title":"Successful Treatment With Isavuconazole of Subcutaneous Phaeohyphomycosis in a Kidney Transplant Recipient","volume":"21","author":"Dalla Gasperina","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.riam.2018.05.002","article-title":"Invasive Aspergillosis in Solid Organ Transplantation","volume":"35","author":"Silva","year":"2018","journal-title":"Rev Iberoam Micol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13313","DOI":"10.1111\/tid.13313","article-title":"Successful Treatment of Aspergillus fumigatus Sternal Osteomyelitis With Isavuconazole in a Heart Transplant Recipient","volume":"22","author":"Assaf","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7323755","DOI":"10.1155\/2022\/7323755","article-title":"Azole-Induced Myositis After Combined Lung-Liver Transplantation","volume":"2022","author":"Happaerts","year":"2022","journal-title":"Case Rep Transpl"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16156","DOI":"10.20452\/pamw.16156","article-title":"Colon Mucormycosis With Renal Spread Resistant to Lipid Complex Amphotericin and Isavuconazole Treatment in a Heart Transplant Recipient","volume":"132","author":"Lango-Maziarz","year":"2022","journal-title":"Pol Arch Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e01240","DOI":"10.1016\/j.idcr.2021.e01240","article-title":"Cerebral and Pulmonary Phaeohyphomycosis Due Cladophialophora Bantiana in an Immunocompromised Patient","volume":"25","author":"Hernandez","year":"2021","journal-title":"IDCases"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e12878","DOI":"10.1111\/tid.12878","article-title":"Isavuconazole Pharmacokinetics in a Patient With Cystic Fibrosis Following Bilateral Orthotopic Lung Transplantation","volume":"20","author":"Kabulski","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jcpt.12308","article-title":"Drug-Drug Interaction Between Isavuconazole and Tacrolimus: A Case Report Indicating the Need for Tacrolimus Drug-Level Monitoring","volume":"40","author":"Kim","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole Versus Voriconazole for Primary Treatment of Invasive Mould Disease Caused by Aspergillus and Other Filamentous Fungi (SECURE): A Phase 3, Randomised-Controlled, Non-Inferiority Trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole Treatment for Mucormycosis: A Single-Arm Open-Label Trial and Case-Control Analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/myc.13298","article-title":"Invasive Aspergillosis in Solid Organ Transplantation: Diagnostic Challenges and Differences in Outcome in a Spanish National Cohort (Diaspersot Study)","volume":"64","author":"Gioia","year":"2021","journal-title":"Mycoses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e12898","DOI":"10.1111\/tid.12898","article-title":"Epidemiology, Risk Factors and Outcomes of Invasive Aspergillosis in Solid Organ Transplant Recipients in the Swiss Transplant Cohort Study","volume":"20","author":"Neofytos","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/ajt.13837","article-title":"Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study","volume":"16","author":"Lopez-Medrano","year":"2016","journal-title":"Am J Transpl"},{"key":"B33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3390\/pharmaceutics13111961","article-title":"The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles","volume":"13","author":"Czyrski","year":"2021","journal-title":"Pharmaceutics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e00970","DOI":"10.1128\/AAC.00970-17","article-title":"Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus Among Solid-Organ Transplant Patients","volume":"61","author":"Rivosecchi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e01643","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2023.11845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T23:11:42Z","timestamp":1702595502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2023.11845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":36,"alternative-id":["10.3389\/ti.2023.11845"],"URL":"https:\/\/doi.org\/10.3389\/ti.2023.11845","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"article-number":"11845"}}